FDA panel OKs Johnson & Johnson single-dose COVID-19 vaccine

More On:

COVID vaccine

British invasion: UK variant now accounts for 10 percent of COVID cases in US

Meet the vaccine appointment bots, and their foes

These snakes may be the key to an effective COVID-19 vaccine

Queen Elizabeth urges Brits to get vaccinated, says jab ‘didn’t hurt’

A panel of expert advisers to the US Food and Drug Administration on Friday recommended that the agency approve the use of Johnson & Johnson’s single-dose COVID-19 vaccine — clearing a path for the shot to be rolled out across the country.

The FDA is likely to authorize the vaccine within the coming days. Once approved, the shot would be the third COVID-19 vaccine available in the US, after the two-dose vaccines made by Pfizer and Moderna.

The FDA panelists voted unanimously that the benefits of the Johnson & Johnson vaccine outweighed any risks.

Johnson & Johnson has pledged to deliver 20 million doses by the end of March and 100 million by late June, which would give a much-needed boost to the country’s vaccine supply.

The Biden administration said earlier this week that it anticipates shipping out 3 to 4 million doses of Johnson & Johnson’s COVID-19 vaccine next week if the FDA green-lights it for emergency use.

With Post wires

Share this article:

Source: Read Full Article